| Q94697175 | Q94697175 |
| Q40985813 | A cost-effective approach to the patient with peptic ulcer bleeding |
| Q41388280 | A practical guide to the management of bleeding ulcers |
| Q42264807 | Abolition by omeprazole of aspirin induced gastric mucosal injury in man. |
| Q67919629 | Acid Peptic Disease in the Elderly |
| Q38031400 | Adverse drug reactions. An overview of special considerations in the management of the elderly patient |
| Q37974166 | Adverse reactions and interactions with aspirin. Considerations in the treatment of the elderly patient |
| Q35715106 | Adverse reactions as a cause of hospital admission in the aged |
| Q39524616 | Aetiology of ulcers |
| Q72729270 | Application of dual radiotelemetric technique in studying drug-drug interaction between diclofenac sodium and ranitidine HCl in volunteers |
| Q42780908 | Are altered pharmacokinetics of non-steroidal anti-inflammatory drugs (NSAIDs) a risk factor for gastrointestinal bleeding? |
| Q34087323 | Articular cartilage and osteoarthrosis. The role of molecular markers to monitor breakdown, repair and disease. |
| Q35705319 | Aspirin and bleeding peptic ulcers in the elderly |
| Q34358573 | Aspirin-induced gastric mucosal damage: prevention by enteric-coating and relation to prostaglandin synthesis |
| Q36723710 | Audit of mortality in upper gastrointestinal bleeding |
| Q36682192 | Changes in birth-cohort pattern of peptic ulcer mortality in England and Wales |
| Q39469724 | Choice of non-steroidal anti-inflammatory drug in persons treated for dyspepsia |
| Q40390646 | Chronic pain--challenge and response |
| Q77413316 | Clinical implications of prostaglandin inhibition in the small bowel |
| Q43263960 | Clinical pharmacology and therapeutics |
| Q40589567 | Clinical presentation and treatment of arthritis in the aged. |
| Q72737138 | Colitis associated with non-steroidal anti-inflammatory drugs |
| Q35973459 | Comorbidity profiles of chronic migraine sufferers in a national database in Taiwan |
| Q74624224 | Comparative safety evaluation of non-narcotic analgesics |
| Q44651019 | Comparison of the gastroduodenal tolerance of tenoxicam and diclofenac Na. A double-blind, endoscopically controlled study in healthy volunteers |
| Q74829293 | Cost, benefits and unintended gastrointestinal side effects of pharmaceutical therapy |
| Q33813174 | Current status of nonsteroidal anti-inflammatory drug (NSAID) use in the United States: risk factors and frequency of complications |
| Q80686341 | Cytoprotection and healing: two unequal brethren |
| Q41883036 | Dangers of NSAIDs in the elderly |
| Q34287826 | Did the drug do it? |
| Q96303862 | Direct detection of diclofenac radical produced by ultraviolet irradiation using electron spin resonance method |
| Q28175558 | Doubt and certainty about nonsteroidal anti-inflammatory drugs in the year 2000: a multidisciplinary expert statement |
| Q39538361 | Drug treatment of pain in rheumatoid disorders |
| Q36723868 | Economic evaluation of gastric ulcer prophylaxis in patients with arthritis receiving non-steroidal anti-inflammatory drugs |
| Q34417829 | Effect in man of aspirin, standard indomethacin, and sustained release indomethacin preparations on gastric bleeding |
| Q34376938 | Effect of Helicobacter pylori colonisation on gastric mucosal eicosanoid synthesis in patients taking non-steroidal anti-inflammatory drugs |
| Q44943579 | Effect of combined anticoagulation and low-dose aspirin treatment on upper gastrointestinal bleeding |
| Q33564029 | Effect of misoprostol on concentrations of prostaglandins in synovial fluid |
| Q39898888 | Effect of non-steroidal anti-inflammatory drugs on dyspeptic symptoms |
| Q69487191 | Effect of ranitidine on gastroduodenal mucosal damage induced by nonsteroidal antiinflammatory drugs |
| Q28195499 | Effect of various doses of palm vitamin E and tocopherol on aspirin-induced gastric lesions in rats |
| Q40442987 | Effects of Nonsteroidal Antiinflammatory Drugs on Platelet Function and Systemic Hemostasis |
| Q54242638 | Effects of nonsteroidal, antiinflammatory drugs on gastrointestinal injury and prostanoid generation in healthy volunteers |
| Q45769912 | Effects of prior use of non-steroidal anti-inflammatory drugs on renal function and transfusion requirements after upper gastrointestinal haemorrhage |
| Q28212868 | Epidemiology of gastroduodenal complications associated with nonsteroidal anti-inflammatory drug use |
| Q40661010 | Epidemiology of gastrointestinal damage associated with nonsteroidal anti-inflammatory drugs |
| Q41757692 | Epidemiology of nonsteroidal anti-inflammatory drug-associated gastrointestinal injury |
| Q44627868 | Eradication of Helicobacter pylori improves the healing rate and reduces the relapse rate of nonbleeding ulcers in patients with bleeding peptic ulcer |
| Q38254644 | Etodolac, a new nonsteroidal anti-inflammatory drug: gastrointestinal microbleeding and endoscopic studies |
| Q36098013 | Evaluation of two doses of etoricoxib, a COX-2 selective non-steroidal anti-inflammatory drug (NSAID), in the treatment of Rheumatoid Arthritis in a double-blind, randomized controlled trial |
| Q50616830 | Excess costs from gastrointestinal disease associated with nonsteroidal anti-inflammatory drugs. |
| Q34397868 | Failure of ethamsylate to reduce aspirin-induced gastric mucosal bleeding in humans |
| Q40466622 | From peptic ulcer disease to NSAID gastropathy. An evolving nosology. |
| Q71605023 | Gastric tolerability of nimesulide. A double-blind comparison of 2 oral dosage regimens and placebo |
| Q36683525 | Gastro-duodenal injury associated with intake of 100-325 mg aspirin daily |
| Q40714847 | Gastroduodenal disease in the elderly patient |
| Q34402529 | Gastrointestinal blood loss after non-steroidal anti-inflammatory drugs. Measurement by selective determination of faecal porphyrins. |
| Q33676713 | Gastrointestinal effects of nonsteroidal anti-inflammatory therapy |
| Q28191970 | Gastrointestinal safety of COX-2 specific inhibitors |
| Q77142022 | Gastrointestinal side effects of nonsteroidal anti-inflammatory drugs |
| Q68343279 | Gastrointestinal ulcerations induced by anti-inflammatory drugs in rats. Physicochemical and biochemical factors involved |
| Q67908572 | Guidelines for good practice in and audit of the management of upper gastrointestinal haemorrhage. Report of a joint working group of the British Society of Gastroenterology, the Research Unit of the Royal College of Physicians of London and the Aud |
| Q31881401 | Helicobacter pylori and nonsteroidal anti-inflammatory drugs: interaction with proton pump inhibitor therapy for prevention of nonsteroidal anti-inflammatory drug ulcers and ulcer complications--future research needs |
| Q72897473 | Helicobacter pylori infection, ABO blood group, and effect of misoprostol on gastroduodenal mucosa in NSAID-treated patients with rheumatoid arthritis |
| Q42186702 | Human gastric mucosal bleeding induced by low dose aspirin, but not warfarin |
| Q69903438 | Incidence of NSAID-related, severe gastrointestinal bleeding |
| Q69911680 | Incidence of perforated and bleeding peptic ulcers before and after the introduction of H2-receptor antagonists |
| Q34505003 | Incidence of serious upper gastrointestinal bleeding/perforation in the general population: review of epidemiologic studies |
| Q34310573 | Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project) |
| Q42091676 | Influence of non-steroidal anti-inflammatory drugs on the outcome of faecal occult blood tests in screening for colorectal cancer |
| Q72400525 | Interrelationships between Helicobacter pylori infection, nonsteroidal antiinflammatory drugs and gastroduodenal disease. A prospective study in healthy volunteers |
| Q43070489 | Intravenous analgesia |
| Q37833512 | Is there a rational basis for the different spectra of adverse effects of nonsteroidal anti-inflammatory drugs (NSAIDs)? |
| Q34408405 | Late mortality in elderly patients surviving acute peptic ulcer bleeding |
| Q36885144 | Long term acid suppressing treatment in general practice |
| Q35705841 | Maintenance treatment with H2 receptor antagonists in patients with peptic ulcer disease: rarely justified in terms of cost or patient benefit |
| Q33557672 | Management of NSAID induced gastrointestinal disturbance |
| Q35920722 | Management of gastroduodenopathy associated with use of nonsteroidal anti-inflammatory drugs |
| Q37785035 | Mechanisms of NSAID-induced gastroenteropathy |
| Q93532042 | Misoprostol and ulcer prophylaxis |
| Q35448618 | Misoprostol in the prevention of gastroduodenal damage in rheumatology |
| Q69172637 | Misoprostol reduces gastroduodenal injury from one week of aspirin: an endoscopic study |
| Q36911181 | Misoprostol--a logical therapeutic approach to gastroduodenal mucosal injury induced by non-steroidal anti-inflammatory drugs? |
| Q33560264 | Misoprostol: pharmacoeconomics of its use as prophylaxis against gastroduodenal damage induced by nonsteroidal anti-inflammatory drugs |
| Q34375359 | Mucosal adaptation to indomethacin induced gastric damage in man--studies on morphology, blood flow, and prostaglandin E2 metabolism |
| Q57945636 | NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND HOSPITAL ADMISSION FOR PERFORATED PEPTIC ULCER |
| Q68748027 | NSAIDs and peptic ulcers |
| Q36526925 | Non-steroidal anti-inflammatory drug associated ulcer: Epidemiology, causation and treatment |
| Q36723729 | Non-steroidal anti-inflammatory drug ingestion: retrospective study of 272 bleeding or perforated peptic ulcers |
| Q36517019 | Non-steroidal anti-inflammatory drug-induced gastroduodenal injury: therapeutic recommendations |
| Q33810501 | Non-steroidal anti-inflammatory drugs (NSAIDs) and gastro-intestinal toxicity: current issues |
| Q42844010 | Non-steroidal anti-inflammatory drugs and elderly patients |
| Q34527487 | Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration |
| Q35704007 | Non-steroidal anti-inflammatory drugs and pain free peptic ulceration in the elderly |
| Q69148393 | Non-steroidal anti-inflammatory drugs and peptic ulceration |
| Q35167288 | Non-steroidal anti-inflammatory drugs and peptic ulcers |
| Q43172651 | Non-steroidal anti-inflammatory drugs and serious gastrointestinal adverse reactions |
| Q93721275 | Non-steroidal anti-inflammatory drugs and serious gastrointestinal adverse reactions |
| Q51014501 | Non-steroidal anti-inflammatory drugs and variceal bleeding: a case-control study. |
| Q35707355 | Non-steroidal anti-inflammatory drugs in patients with peptic ulcer disease: rarely justified in terms of cost or patient benefit |
| Q35707627 | Non-steroidal anti-inflammatory drugs in patients with peptic ulcer disease: to be considered in certain circumstances |
| Q37717338 | Non-steroidal anti-inflammatory drugs versus simple analgesics in the treatment of arthritis |
| Q43110475 | Non-steroidal anti-inflammatory drugs--prescribe with caution |
| Q40561183 | Nonsteroidal anti-inflammatory drug-induced enteropathy: case discussion and review of the literature |
| Q41078785 | Nonsteroidal anti-inflammatory drug-induced gastrointestinal injury |
| Q72897451 | Nonsteroidal antiinflammatory drugs and lower gastrointestinal bleeding |
| Q67742789 | Nonsteroidal antiinflammatory drugs and mortality from peptic ulceration in West Germany: 1952?1989 |
| Q39403304 | Nonsteroidal antiinflammatory drugs and upper gastrointestinal hemorrhage in an urban hospital |
| Q50956118 | Nonsteroidal antiinflammatory drugs are associated with both upper and lower gastrointestinal bleeding. |
| Q73502258 | Nonsteroidal antiinflammatory drugs, ulcers and risk:A collaborative meta-analysis |
| Q81445235 | Occult GI bleeding in NSAID users--the base of the iceberg! |
| Q40466638 | Osteoarthritis in the aged. Epidemiological issues and optimal management. |
| Q37440025 | Oxidative stress induces gastric submucosal arteriolar dysfunction in the elderly |
| Q37213534 | PMK-S005 Alleviates Age-Related Gastric Acid Secretion, Inflammation, and Oxidative Status in the Rat Stomach |
| Q41787031 | Pain control in advanced cancer: pharmacological methods. |
| Q68324054 | Peptic Ulcer Bleeding Today: Risk Factors and Characteristics of the Disease |
| Q81722666 | Peptic ulcer and non-steroidal anti-inflammatory agents |
| Q34393709 | Peptic ulcer disease: absence of antibodies stimulating the histamine sensitive adenylate cyclase of gastric mucosal cells |
| Q68406057 | Peptic ulcer in rheumatoid arthritis |
| Q36894510 | Peptic ulceration |
| Q33560292 | Pharmacoeconomic consequences of measurement and modification of hospital drug use. |
| Q33560258 | Pharmacoeconomics of nonsteroidal anti-inflammatory drugs (NSAIDs). |
| Q69316438 | Pharmacokinetics of naproxen in elderly patients |
| Q70175576 | Pharmacology and significance of nonsteroidal anti-inflammatory drugs in the treatment of skin diseases |
| Q35223220 | Piroxicam and other cyclooxygenase inhibitors: Potential for cancer chemoprevention |
| Q34379031 | Predicting NSAID related ulcers--assessment of clinical and pathological risk factors and importance of differences in NSAID |
| Q77463916 | Preoperative irradiation versus the use of nonsteroidal anti-inflammatory drugs for prevention of heterotopic ossification following total hip replacement: the results of a randomized trial |
| Q35704624 | Prevention of gastroduodenal damage induced by non-steroidal anti-inflammatory drugs: controlled trial of ranitidine |
| Q41848139 | Prophylactic aspirin and risk of peptic ulcer bleeding |
| Q33563480 | Prophylaxis against non-steroidal induced upper gastrointestinal side effects |
| Q31881389 | Prospects for changing the burden of nonsteroidal anti-inflammatory drug toxicity |
| Q39524637 | Prostaglandin analogues |
| Q69889133 | Prostaglandins for peptic ulcer: a promise unfulfilled |
| Q34527888 | Randomised study of the influence of non-steroidal anti-inflammatory drugs on the treatment of peptic ulcer in patients with rheumatic disease |
| Q73929227 | Randomized trial comparing early postoperative irradiation vs. the use of nonsteroidal antiinflammatory drugs for prevention of heterotopic ossification following prosthetic total hip replacement |
| Q43492439 | Ranitidine prevents duodenal ulcers associated with non-steroidal anti-inflammatory drug therapy |
| Q73390997 | Recent nonsteroidal anti-inflammatory drug use increases the risk of early recurrence of bleeding in patients presenting with bleeding ulcer |
| Q93724356 | Relapse of duodenal ulcer: Author's reply |
| Q34394177 | Relation of upper gastrointestinal bleeding to non-steroidal anti-inflammatory drugs and aspirin: a case-control study |
| Q34072730 | Repeat prescribing of non-steroidal anti-inflammatory drugs excluding aspirin: how careful are we? |
| Q40816610 | Rheumatoid arthritis in the aged. Incidence and optimal management |
| Q34407762 | Rising death rate from non-malignant disease of the oesophagus (NMOD) in England and Wales |
| Q69877701 | Rising frequency of ulcer perforation in elderly people in the United Kingdom |
| Q68759748 | Risk of acute upper gastrointestinal bleeding in patients with ulcerative disease and treatment with non-steroidal anti-inflammatory drugs (NSAIDs). Results from the Comprehensive Hospital Drug Monitoring Berne (CHDM) |
| Q50989183 | Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. |
| Q50966892 | Role of Helicobacter pylori infection on upper gastrointestinal bleeding in the elderly: a case-control study. |
| Q34285112 | Role of drugs in fractures of the femoral neck |
| Q35133300 | Selective Outpatient Management of Upper Gastrointestinal Bleeding in the Elderly: Results from the SOME Bleeding Study |
| Q42061798 | Short-term effects of antirheumatic drugs |
| Q57386566 | Side-effects of non-steroidal anti-inflammatory drugs |
| Q34418047 | Suspected adverse drug reactions in elderly patients reported to the Committee on Safety of Medicines |
| Q39524599 | Techniques related to the clinical epidemiology of peptic ulcer disease |
| Q44779582 | The Management of Non-Steroidal Anti-Inflammatory Drug-Induced Gastroduodenal Ulcers |
| Q36972832 | The Problems and Pitfalls of NSAID Therapy in the Elderly (Part II)1 |
| Q37331026 | The acid-secreting parietal cell as an endocrine source of Sonic Hedgehog during gastric repair |
| Q35841154 | The aging stomach: implications for NSAID gastropathy |
| Q33543093 | The epidemiology of serious adverse drug reactions among the elderly |
| Q28367917 | The histopathology of non-steroidal anti-inflammatory drug induced gastroduodenal damage: correlation with Helicobacter pylori, ulcers, and haemorrhagic events |
| Q34402563 | The influence of an academic representative on prescribing by general practitioners |
| Q37717322 | The management of NSAID gastropathy |
| Q39761044 | The pharmacokinetics of non-steroidal anti-inflammatory drugs in the elderly |
| Q41537400 | The risks and costs of upper gastrointestinal disease attributable to NSAIDs |
| Q38297809 | The role of prostaglandins in gastric mucosal protection |
| Q48567641 | The treatment of lateral epicondylitis by iontophoresis of sodium salicylate and sodium diclofenac |
| Q36067762 | The treatment of osteoarthritis |
| Q34561025 | Toward an epidemiology of gastropathy associated with nonsteroidal antiinflammatory drug use. |
| Q41526041 | Toxicity of Nonsteroidal Anti-Inflammatory Drugs in the Elderly: Is Advanced Age a Risk Factor? |
| Q40385238 | Toxicity of nonsteroidal anti-inflammatory drugs. An overview of the epidemiological evidence. |
| Q35572516 | Treating patients with acute gastrointestinal bleeding or rebleeding |
| Q42106342 | Two cheers for NSAIDs |
| Q28185419 | Ulcer complications associated with anti-inflammatory drug use. What is the extent of the disease burden? |
| Q42556831 | Ulcerogenicity of piroxicam. |
| Q34068129 | Ulcerogenicity of piroxicam: an analysis of spontaneously reported data |
| Q73917891 | Uptake of ibuprofen, indomethacin and ketoprofen into isolated rabbit parietal cells |
| Q34392547 | Value of a centralised approach in the management of haematemesis and melaena: experience in a district general hospital |
| Q74509832 | Variability in risk of gastrointestinal complications with different nonsteroidal anti-inflammatory drugs |
| Q24655364 | Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis |
| Q41905119 | Variations in response to non-steroidal anti-inflammatory drugs |
| Q34528761 | Which peptic ulcer patients bleed? |
| Q67979617 | [Epidemiology and treatment of gastroduodenal lesions caused by non-steroidal anti-inflammatory agents] |
| Q79361493 | [Etiology of upper gastrointestinal bleeding of peptic origin: role of Helicobacter pylori and NSAIDs] |
| Q74136865 | [Prospective study on the prevention of heterotopic ossification after total hip replacement. Non-steroidal anti-inflammatory agents versus radiation therapy] |
| Q36888170 | n of 1 trials comparing a non-steroidal anti-inflammatory drug with paracetamol in osteoarthritis |